|
|
 |
Meet
the
team
 |
Prof. Nigel Courtenay-Luck PhD
CSO/co-founder of Saturn
Nigel was co-founder, CSO and Director Antisoma plc (1990 - 2008). He
is the co-inventor of AS1409. He is also Senior Lecturer, Hammersmith
Hospital, London, Professor at Medical University of South Carolina,
Fellow of the Royal Society of Medicine, member of BIA Scientific
Committee and Director at Fusion Antibodies Ltd.
n.courtenayluck@btinternet.com
|
 |
Raymond Spencer BSc., ACA
CFO/co-founder of Saturn
Raymond has over 25 years experience as CFO in biotech from start-up to
AIM and LSE listed companies. At Antisoma plc (1996 - 2008) he
concluded the IPO in 1998, several fund-raising rounds to
>£100M, the acquisition of two private US biotech companies
and the closing of three licensing deals with big pharma exceeding
$100m in total up-front payments. Raymond is currently CFO of AIM
listed Summit (LSE:SUMM) and CFO and co-founder/Director of MGB
Biopharma Ltd.
raymond.spencer@Bio-CFO.com
|
 |
Gary Acton PhD
Chief Medical Officer
Gary was the CMO of Antisoma plc
(2006 - 2011) and was responsible for the phase I clinical study of
AS1409 and a number of other cancer clinical trials. He was formerly
Managing Director, Cell Therapeutics Europe, VP CLinical Development,
Vernalis plc, Director of Clinical Research Fujisawa Pharmaceuticals,
non-exec Director, Neuropharm Group and Oncologist at Royal Marsden and
St George's Hospitals.
g.acton@live.co.uk
|
| |
|
|
| |
|
|
|
| |
© 2012 Saturn BioSciences
|
|
  |
|
